Literature DB >> 22033780

Pediatric lymphoma: metabolic tumor burden as a quantitative index for treatment response evaluation.

Punit Sharma1, Arun Gupta, Chetan Patel, Sameer Bakhshi, Arun Malhotra, Rakesh Kumar.   

Abstract

OBJECTIVE: Metabolic tumor burden (MTB) incorporates the advantages of the existing indices: the metabolic volume of the lesion calculated by size-dependent thresholding on positron emission tomography-computed tomography (PET-CT) along with its aggressiveness as determined by standardized uptake value (SUV). This study was conducted to investigate whether MTB can be used as an objective index for monitoring therapy response in pediatric lymphoma.
METHODS: Forty-two pediatric patients (35 male and 7 female) with histologically proven lymphomas (26 Hodgkin's and 16 non-Hodgkin's) were evaluated. MTB was assessed in baseline, early interim (after 2 cycles) and post-therapy PET-CT studies using RT_Image software. Size-dependent thresholding based on a phantom study conducted at our institute was used for the calculation of metabolic tumor volume (MTV). MTB was given as the product of MTV and the SUVmean. Summation of MTB from all lesions gave the whole body MTB. Baseline, early interim and post-therapy SUVmax and whole body MTB of the partial and complete response group were compared.
RESULTS: Of 42 patients, 37 had complete response and 5 had partial response at the end of therapy based on clinical, CECT and bone marrow biopsy findings. SUVmax showed an overall reduction of 87.4% while MTB showed a reduction of 96.4% between baseline and early interim PET-CT scan. Similarly, SUVmax showed an overall reduction of 95.2% while MTB showed a reduction of 99.6% between baseline and post-therapy scan. There was significant difference between MTB of partial response and complete response group at baseline and early interim PET-CT (p 0.031 and 0.012, respectively). No such significant difference was found for SUVmax.
CONCLUSION: Whole body MTB appears to be useful quantitative parameter for the assessment of treatment response using PET-CT in pediatric lymphoma patients.

Entities:  

Mesh:

Year:  2011        PMID: 22033780     DOI: 10.1007/s12149-011-0539-2

Source DB:  PubMed          Journal:  Ann Nucl Med        ISSN: 0914-7187            Impact factor:   2.668


  9 in total

1.  Baseline total lesion glycolysis measured with (18)F-FDG PET/CT as a predictor of progression-free survival in diffuse large B-cell lymphoma: a pilot study.

Authors:  Shadi A Esfahani; Pedram Heidari; Elkan F Halpern; Ephraim P Hochberg; Edwin L Palmer; Umar Mahmood
Journal:  Am J Nucl Med Mol Imaging       Date:  2013-04-09

2.  Prognostic value of whole-body metabolic tumour volume and total lesion glycolysis measured on ¹⁸F-FDG PET/CT in patients with extranodal NK/T-cell lymphoma.

Authors:  Choon-Young Kim; Chae Moon Hong; Do-Hoon Kim; Seung Hyun Son; Shin Young Jeong; Sang-Woo Lee; Jaetae Lee; Byeong-Cheol Ahn
Journal:  Eur J Nucl Med Mol Imaging       Date:  2013-05-15       Impact factor: 9.236

3.  Prognostic role of baseline 18F-FDG PET/CT metabolic parameters in Burkitt lymphoma.

Authors:  Domenico Albano; Giovanni Bosio; Chiara Pagani; Alessandro Re; Alessandra Tucci; Raffaele Giubbini; Francesco Bertagna
Journal:  Eur J Nucl Med Mol Imaging       Date:  2018-10-02       Impact factor: 9.236

4.  Prognostic Value of Metabolic Tumor Volume Estimated by (18) F-FDG Positron Emission Tomography/Computed Tomography in Patients with Diffuse Large B-Cell Lymphoma of Stage II or III Disease.

Authors:  Jihyun Kim; Junshik Hong; Seog Gyun Kim; Kyung Hoon Hwang; Minsu Kim; Hee Kyung Ahn; Sun Jin Sym; Jinny Park; Eun Kyung Cho; Dong Bok Shin; Jae Hoon Lee
Journal:  Nucl Med Mol Imaging       Date:  2014-05-29

5.  Pediatric Hodgkin Lymphoma: Predictive value of interim 18F-FDG PET/CT in therapy response assessment.

Authors:  Cristina Ferrari; Artor Niccoli Asabella; Nunzio Merenda; Corinna Altini; Margherita Fanelli; Paola Muggeo; Francesco De Leonardis; Teresa Perillo; Nicola Santoro; Giuseppe Rubini
Journal:  Medicine (Baltimore)       Date:  2017-02       Impact factor: 1.889

6.  Prediction of Overall Survival and Progression-Free Survival by the 18F-FDG PET/CT Radiomic Features in Patients with Primary Gastric Diffuse Large B-Cell Lymphoma.

Authors:  Yi Zhou; Xue-Lei Ma; Lu-Tong Pu; Ruo-Fan Zhou; Xue-Jin Ou; Rong Tian
Journal:  Contrast Media Mol Imaging       Date:  2019-10-30       Impact factor: 3.161

7.  Automated quantification of baseline imaging PET metrics on FDG PET/CT images of pediatric Hodgkin lymphoma patients.

Authors:  Amy J Weisman; Jihyun Kim; Inki Lee; Kathleen M McCarten; Sandy Kessel; Cindy L Schwartz; Kara M Kelly; Robert Jeraj; Steve Y Cho; Tyler J Bradshaw
Journal:  EJNMMI Phys       Date:  2020-12-14

8.  The usefulness of (18)F-FDG PET/CT for assessing methotrexate-associated lymphoproliferative disorder (MTX-LPD).

Authors:  Shiro Watanabe; Osamu Manabe; Kenji Hirata; Noriko Oyama-Manabe; Naoya Hattori; Yasuka Kikuchi; Kentaro Kobayashi; Takuya Toyonaga; Nagara Tamaki
Journal:  BMC Cancer       Date:  2016-08-15       Impact factor: 4.430

9.  The Utility of Metabolic Parameters on Baseline F-18 FDG PET/CT in Predicting Treatment Response and Survival in Paediatric and Adolescent Hodgkin Lymphoma.

Authors:  Janet Denise Reed; Andries Masenge; Ane Buchner; Fareed Omar; David Reynders; Mariza Vorster; Christophe Van de Wiele; Mike Sathekge
Journal:  J Clin Med       Date:  2021-12-20       Impact factor: 4.241

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.